The links between neuroinflammation, brain structure and depressive disorder: A cross-sectional study protocol

• Published in: PloS one 2024-11, Vol.19 (11), p.e0311218
• Main Authors: Milasauskiene, Egle, Burkauskas, Julius, Jesmanas, Simonas, Gleizniene, Rymante, Borutaite, Vilmante, Skemiene, Kristina, Vaitkiene, Paulina, Adomaitiene, Virginija, Lukosevicius, Saulius, Gradauskiene, Brigita, Brown, Guy, Steibliene, Vesta
• Format: Article
• Language: English
• Subjects: Adult; Antidepressants; Biology and Life Sciences; Blood levels; Blood plasma; Blood-brain barrier; Body mass index; Body size; Brain; Brain - diagnostic imaging; Brain - metabolism; Brain - pathology; Brain research; Cognition; Cognitive ability; Cross-Sectional Studies; Cytokines; Cytokines - blood; Depressive Disorder, Major - blood; Depressive Disorder, Major - pathology; Diagnosis; Disease; Evaluation; Female; Genes; Health problems; Humans; Hypotheses; Immune system; Inflammation; Kinases; Lipopolysaccharides; Lipopolysaccharides - blood; Magnetic permeability; Magnetic resonance; Magnetic Resonance Imaging; Major depressive disorder; Male; Medicine and Health Sciences; Membrane permeability; Mental depression; Mental disorders; Middle Aged; Nervous system; Neurodegeneration; Neurogenesis; Neuroimaging; Neuroinflammatory Diseases - blood; Neuroinflammatory Diseases - pathology; Neuropsychological Tests; Permeability; Plasma; Remission (Medicine); Research and Analysis Methods; Risk factors; Serotonin; Signs and symptoms; Social Sciences; Statistical analysis; Structure; Study Protocol
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0311218

It is known that symptoms of major depressive disorder (MDD) are associated with neurodegeneration, that lipopolysaccharide (LPS) can induce symptoms of MDD, and that blood LPS levels are elevated in neurodegeneration. However, it is not known whether blood LPS and cytokine levels correlate with MDD, cognition and brain structure, and this is tested in this study. This cross-sectional study includes individuals with MDD (n = 100) and a control group of individuals with no one-year history of a mental disorder (n = 50). A comprehensive evaluation is performed, including the collection of basic sociodemographic information, data on smoking status, body mass index, course of MDD, past treatment, comorbid diseases, and current use of medications. Diagnosis of MDD is performed according to the WHO's [2019] International Classification of Diseases and related health problems by psychiatrist and severity of MDD is evaluated using the Montgomery-Åsberg Depression Scale. The Cambridge Neuropsychological Test Automated Battery is used to evaluate cognitive functioning. Venous blood samples are taken to measure genetic and inflammatory markers, and multiparametric brain magnetic resonance imaging is performed to evaluate for blood-brain barrier permeability, structural and neurometabolic brain changes. Descriptive and inferential statistics, including linear and logistic regression, will be used to analyse relationships between blood plasma LPS and inflammatory cytokine concentrations in MDD patients and controls. The proposed sample sizes are suitable for identifying significant differences between the groups, according to a power analysis. Trial registration: Clinicaltrials.gov NCT06203015.